✦ LIBER ✦

Radiotherapy planning complexity and survival after treatment of advanced stage lung cancer in the elderly

✍ Scribed by Benjamin Goldsmith; Jamie Cesaretti; Juan P. Wisnivesky

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 165 KB
Volume: 115
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.24512

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Decreased metastasis and improved surviv

Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer

✍ Sachin S. Kamath; Dean L. McCarley; Robert A. Zlotecki 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

In an attempt to verify the relative efficacy of early concurrent vs. sequential timing of thoracic radiotherapy (TRT) and platinum/etoposide chemotherapy, 48 patients with limited-stage small cell lung cancer treated with either early-concurrent (29 patients) or sequential (19 patients) TRT and pla

Disparities in the application of adjuva

Disparities in the application of adjuvant radiotherapy after breast-conserving surgery for early stage breast cancer : Impact on overall survival

✍ Anthony E. Dragun; Bin Huang; Thomas C. Tucker; William J. Spanos 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 271 KB 👁 1 views

The value of combined-modality therapy i

The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer

✍ Steven E. Schild; Sumithra J. Mandrekar; Aminah Jatoi; William L. McGinnis; Phil 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 2 views

## Abstract ## BACKGROUND. The objective of this study was to assess the value of combined‐modality therapy in elderly patients by comparing the differences in outcome between patients who received radiotherapy (RT) alone and patients who received RT plus chemotherapy for stage III nonsmall cell l

Tumor response and progression-free surv

Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer : Findings on the basis of North Central Cancer Treatment Group trials

✍ Nathan R. Foster; Yingwei Qi; Qian Shi; James E. Krook; John W. Kugler; James R. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

The possible advantage of hyperfractiona

The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma : Results of a North Central Cancer Treatment Group Phase III study

✍ James A. Bonner; William L. McGinnis; Phillip J. Stella; Robert F. Marschke Jr.; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

## BACKGROUND. A three-arm Phase III randomized trial was performed

Weekly docetaxel in the treatment of eld

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma : A Minnie Pearl Cancer Research Network Phase II Trial

✍ John D. Hainsworth; Howard A. Burris III; Sharlene Litchy; Lisa H. Morrissey; Jo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 3 views

## Background: Weekly administration of docetaxel was found to reduce myelosuppression and other nonhematologic toxicities when compared with administration every 3 weeks. in the current phase ii trial, the authors evaluated the feasibility, toxicity, and efficacy of weekly docetaxel in the treatme